Holen Sie sich die Stockscreener-App
2.465
3.15%
-0.075
Schlusskurs vom Vortag:
$2.54
Offen:
$2.6
24-Stunden-Volumen:
669.84K
Relative Volume:
0.37
Marktkapitalisierung:
$240.63M
Einnahmen:
$40.52M
Nettoeinkommen (Verlust:
$-160.06M
KGV:
-1.3088
EPS:
-1.8834
Netto-Cashflow:
$-165.85M
1W Leistung:
+23.01%
1M Leistung:
+39.78%
6M Leistung:
-8.55%
1J Leistung:
+79.57%
1-Tages-Spanne:
$2.4517
$2.64
1-Wochen-Bereich:
$1.975
$2.765
52-Wochen-Spanne:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.465 | 247.95M | 40.52M | -160.06M | -165.85M | -1.8834 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.70 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.79 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.66 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.82 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.42 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas Medicine at Barclays Conference: Strategic Focus on CRISPR Innovation - Investing.com Canada
Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects - TipRanks
Editas Medicine (EDIT) Receives Upgrade to 'Buy' from Jones Trad - GuruFocus
Editas Medicine (NASDAQ:EDIT) Upgraded at JonesTrading - MarketBeat
Jones Trading upgrades Editas Medicine stock rating on gene therapy progress - Investing.com Canada
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - TradingView
Editas Medicine 2025 Annual Report: CRISPR Gene Editing Pipeline, EDIT-401 Program, Intellectual Property, and Industry Competition - Minichart
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates - Bitget
Editas: Q4 Earnings Snapshot - theheraldreview.com
Cowen Maintains Buy on EDIT Editas Medicine, Inc. March 2026 - Meyka
Baird reiterates Editas Medicine stock rating on pipeline progress By Investing.com - Investing.com Canada
Editas Medicine 10-K: $40.5M revenue, $(1.80) EPS - TradingView
Editas Medicine (EDIT): Today's Analyst Rating Insights | EDIT S - GuruFocus
Editas Medicine (NASDAQ:EDIT) Receives "Buy" Rating from Chardan Capital - MarketBeat
TD Cowen reiterates Editas Medicine stock Buy rating on pipeline progress - Investing.com Canada
BREAKING: EDIT Reports Narrower Loss for Q4 EPS, vs. $0.21 per share estimated - AlphaStreet
Editas Medicine earnings beat by $0.17, revenue topped estimates - Investing.com Canada
Editas: Fourth Quarter Financial Overview - Bitget
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Editas Medicine Q4 2025 Financial Report: Loss of $5.6M, Revenue $24.7MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Editas Medicine (EDIT) Reports Fourth Quarter Financials and Advances Gene Editing Strategy - GuruFocus
Editas Medicine posts fourth quarter and full year 2025 financial results - Traders Union
Editas Medicine stock rises 2% after Q4 earnings and revenue beats - Investing.com
Editas Medicine Q4 Earnings Beat Expectations - Intellectia AI
Editas Medicine (NASDAQ:EDIT) Announces Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
Editas Medicine posts smaller‑than‑expected Q4 net loss on lower R&D spend - TradingView
Editas Medicine SVP Parison sells $957 in stock By Investing.com - Investing.com South Africa
Editas Medicine SVP Parison sells $957 in stock - Investing.com
Editas Medicine EVP Burkly sells $1.5k in stock - Investing.com UK
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,394 Shares - MarketBeat
EDIT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Editas Medicine at TD Cowen: Strategic Focus on In Vivo CRISPR - Investing.com Canada
EDIT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Editas Medicine Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Editas Medicine (EDIT) Expected to Announce Earnings on Wednesday - MarketBeat
Editas Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Editas Medicine (NASDAQ:EDIT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
Can Editas Medicine Inc. ride the EV waveQuarterly Profit Report & Weekly Setup with High ROI Potential - mfd.ru
Market Moves: Whats the MACD signal for CARGWeekly Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Signal Recap: Can Editas Medicine Inc disrupt its industryBear Alert & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Aug Movers: Can Editas Medicine Inc. outperform in the next rallyEarnings Risk Report & Reliable Volume Spike Trade Alerts - mfd.ru
Why Editas Medicine Inc. (8EM) stock could be next leaderJuly 2025 Trade Ideas & AI Driven Price Predictions - mfd.ru
Editas Medicine’s Volatile Comeback: Can CRISPR Hype Outrun Clinical Risk? - AD HOC NEWS
Editas Medicine (NASDAQ:EDIT) Share Price Crosses Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Analyst Downgrade: Can Editas Medicine Inc grow without external fundingMarket Performance Summary & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Can Editas Medicine Inc. stock sustain revenue growth2025 Investor Takeaways & Community Shared Stock Ideas - mfd.ru
Can Editas Medicine Inc. disrupt its industryWeekly Gains Report & Daily Momentum Trading Reports - mfd.ru
Companies Like Editas Medicine (NASDAQ:EDIT) Could Be Quite Risky - Yahoo Finance
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com
Editas Medicine (NASDAQ:EDIT) Share Price Crosses Below 50 Day Moving AverageHere's What Happened - MarketBeat
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):